PDF herunterladen
Psychiatr Prax 2020; 47(01): 43-45
DOI: 10.1055/a-0941-3874
Kasuistik
© Georg Thieme Verlag KG Stuttgart · New York

Sexuelle Enthemmung bei Therapie mit Aripiprazol

Hypersexuality Induced by Aripiprazole
Ralf Kozian
Vinzenz von Paul Hospital, Rottweil
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
08. Juli 2019 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Zusammenfassung

Das Auftreten einer Hypersexualität bzw. einer sexuellen Enthemmung bei Anwendung von verschiedenen Neuroleptika stellt eine Rarität dar. Bei Anwendung von Aripiprazol häufen sich jedoch Mitteilungen, nach denen es zu einer sexuellen Enthemmung bzw. auch anderen Impulskontrollstörungen wie dem pathologischen Spielen kommt. Verantwortlich dafür ist möglicherweise der Partialagonismus am D2-Rezeptor oder auch die Stimulation am 5-HT1A-Rezeptor und der 5-HT2A-Rezeptoren-Antagonismus.

Abstract

Hypersexual behavior can be assumed as a rare side effect of treatment with aripiprazole and is possibly due to partial agonism on dopamine receptors or partial agonism on 5-HT1A receptors and 5 HT2A antagonism.

Schlüsselwörter

sexuelle Enthemmung - Aripiprazol

Keywords

hypersexuality - aripiprazole
 

  • Literatur

  • 1 Davidson CK, Johnson T, Jansen K. Risperidone- induced hypersexuality. Br J Psychiatry 2013; 203: 233
    PubMedGoogle Scholar
  • 2 Gomez EA. Hypersexuality in men receiving fluphenazine decanoate. Am J Psychiatry 1981; 138: 1263
    PubMedGoogle Scholar
  • 3 Moore TJ, Glenmullen J, Mattison DR. Reports of pathological gambling, hypersexuality and compulsive shopping associated with dopamine receptor agonist drugs. JAMA Intern Med 2014; 174: 1930-1933
    CrossrefPubMedGoogle Scholar
  • 4 Etminam M, Sodhi M, Samii A. et al. Risk of gambling disorder and impulse control disorder with aripiprazole, pramipexole and ropinirole. J Clin Psychopharmacol 2017; 37: 102-104
    CrossrefPubMedGoogle Scholar
  • 5 Gaboriau L, Victorri-Vigneau C, Gerardin M. et al. Aripiprazole: a new risk factor for pathological gambling? A report of 8 case reports. Addictive Behaviors 2014; 39: 562-565
    CrossrefPubMedGoogle Scholar
  • 6 Gauvadan G, Magalon D, Cohen J. et al. Partial agonist therapy in schizophrenia: relevance to diminished criminal responsibility. J Forensic Sci 2010; 55: 1659-1662
    CrossrefPubMedGoogle Scholar
  • 7 Peterson E, Forlano R. Partial dopamine agonist-induced pathological gambling and impulse-control deficit on low-dose aripiprazole. Australasian Psychiatry 2017; 25: 614-616
    CrossrefPubMedGoogle Scholar
  • 8 Cohen J, Magalon D, Boyer L. et al. Aripiprazole-induced pathological gambling: a report of 3 cases. Current Drug Safety 2011; 6: 51-53
    CrossrefPubMedGoogle Scholar
  • 9 Smith N, Kitchenham N, Bowden-Jones H. Pathological gambling and the treatment of psychosis with aripiprazole: case reports. Br J Psychiatry 2011; 199: 158-159
    CrossrefPubMedGoogle Scholar
  • 10 Grall-Bronnec M, Sauvaget A, Perrouin F. et al. Pathological gambling associated with aripiprazole or dopamine replacement therapy. J Clin Psychopharmacol 2016; 36: 63-70
    CrossrefPubMedGoogle Scholar
  • 11 Mancano MA. Gambling disorder and impulse control disorder with aripiprazole. Hosp Pharm 2017; 52: 253-257
    CrossrefPubMedGoogle Scholar
  • 12 Reddy B, Ali M, Guruprasda S. Hypersexuality induced by aripiprazole: two cases and review of literature. Asian J Psychiatr 2017; 25: 1-3
    CrossrefPubMedGoogle Scholar
  • 13 Cheon EJ, Bon-Hoo K, Sang SS. et al. Two cases of hypersexuality probably associated with aripiprazole. Psychiatry Investig 2013; 10: 200-202
    CrossrefPubMedGoogle Scholar
  • 14 Das S, Chatterjee SS, Bagewadi V. Aripiprazole induced hypersexuality, when we should be cautious?. Asian J Psychiatry 2017; 29: 162-163
    CrossrefPubMedGoogle Scholar
  • 15 Bulbena-Cabre A, Bulbena A. Aripiprazol-induced hypersexuality. Prim Care Companion CNS Disord 2016; 18: 1-2
    PubMedGoogle Scholar
  • 16 Schlachetzki JC, Langosch JM. Aripiprazol induced hypersexuality in a 24-year-old female patient with schizoaffective disorder?. J Clin Psychopharmacol 2008; 28: 567-568
    CrossrefPubMedGoogle Scholar
  • 17 Benkert O, Hippius H. Hrsg. Kompendium der psychiatrischen Pharmakotherapie. Heidelberg: Springer; 2018
    Google Scholar
  • 18 Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psy 2006; 14: 191-210
    PubMedGoogle Scholar
  • 19 Tan L, Wang HF, Wang J. et al. Efficacy and safety of atypical antipsychotic drug treatment for dementia: a systematic review and metaanalysis. Alzheimer Res Ther 2015; 7: 20
    PubMedGoogle Scholar
  • 20 Snoeren EMS, Veening JG, Olivier B. et al. Serotonin 1A receptors and sexual behavior in male rats: a review. Pharmacology, Biochemistry and Behavior 2014; 121: 102-114
    CrossrefPubMedGoogle Scholar
  • 21 Oosting RS, Chan JS, Olivier B. et al. Differential effects of vilazodone versus citalopram and paroxetine on sexual behavior and serotonin transporters in male rats. Psychopharmacology 2016; 233: 1025-1034
    CrossrefPubMedGoogle Scholar